Head-To-Head Comparison: CRISPR Therapeutics (CRSP) and Its Peers

CRISPR Therapeutics (NASDAQ:CRSP) is one of 846 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare CRISPR Therapeutics to similar businesses based on the strength of its analyst recommendations, institutional ownership, profitability, valuation, earnings, risk and dividends.

Profitability

This table compares CRISPR Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-1,812.07%	-25.59%	-17.89%
CRISPR Therapeutics Competitors	-12,285.98%	-196.04%	-30.61%

Earnings & Valuation

This table compares CRISPR Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CRISPR Therapeutics	$23.32 million	-$581.60 million	-9.53
CRISPR Therapeutics Competitors	$729.47 million	$11.46 million	-14.85

CRISPR Therapeutics’ rivals have higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

CRISPR Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics’ rivals have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for CRISPR Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1	6	8	2	2.65
CRISPR Therapeutics Competitors	9905	15274	45607	1595	2.54

CRISPR Therapeutics currently has a consensus price target of $72.93, suggesting a potential upside of 61.53%. As a group, “Biotechnology” companies have a potential upside of 99.55%. Given CRISPR Therapeutics’ rivals higher possible upside, analysts plainly believe CRISPR Therapeutics has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

CRISPR Therapeutics beats its rivals on 8 of the 13 factors compared.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.